Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1273 • ACR Convergence 2021
A 12-week Aerobic Exercise Training Program in Women with Systemic Lupus Erythematosus (SLE) Improves Fatigue, Mitochondrial Dysfunction and Associated Interferon Gene Signature
Sarfaraz Hasni¹, Marquis Chapman², Rebekah Feng¹, Anam Ahmad¹, Sarthak Gupta³, Mohammad Naqi¹, Adam Munday¹, Shajia Lu¹, Massimo Gadina², Zerai Manna¹, Xiaobai Li⁴, Yinghui Shi¹, Kalyani Mishra-Thakur¹, Michael Davis⁵, Jun Chu³, Elaine Poncio⁶, Yenealem Temesgen-Oyelakin⁷, Jonathan Martinez¹, Zoe Morris¹, Isabel Ochoa⁶, Shuichiro Nakabo⁸, Bart Drinkard¹, Gayle McCrossin¹, Marybeth Stockman¹, Mariana Kaplan¹, Leorey Saligan¹, Randall Keyser⁹, Leighton Chan¹ and Lisa Chin¹, ¹National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴Clinical Center, National Institutes of Health, Bethesda, MD, ⁵NIAMS, Bethesda, MD, ⁶NIH/NIAMS, Bethesda, MD, ⁷National Institutes of Health (NIH), Bethesda, MD, ⁸NIAMS/NIH, Bethesda, MD, ⁹George Mason University, Bethesda
Background/Purpose: Fatigue in SLE patients is ubiquitous and is reported as one of the most debilitating symptoms. Yet mechanisms underlying the pathophysiology of SLE-related fatigue…
Abstract Number: 1289 • ACR Convergence 2021
Patients Enrolled in the Accelerating Medicines Partnership (AMP) RA/SLE Network with Isolated Renal Disease Report Minimal Quality of Life Impairment on PROMIS-29 Compared to Patients with Extrarenal Symptoms
Philip Carlucci¹, Jessica Li², Heather Gold³, Kristina Deonaraine¹, Andrea Fava², Jill Buyon⁴, Judith James⁵, Chaim Putterman⁶, Deepak Rao⁷, Betty Diamond⁸, Derek Fine², Jose Monroy-Trujillo², Kristin Haag⁹, Accelerating Medicines Partership (AMP) RA/SLE Network¹⁰, H. Michael Belmont⁴, Sean Connery¹¹, Fernanda Payan-Schober¹², Richard Furie¹³, Celine Berthier¹⁴, Maria Dall'Era¹⁵, Kerry Cho¹⁶, Diane Kamen¹⁷, Kenneth Kalunian¹⁸, The Accelerating Medicines Parternship In SLE Network¹⁹, Peter Izmirly¹ and Michelle Petri²⁰, ¹New York University School of Medicine, New York, NY, ²Johns Hopkins University, Baltimore, MD, ³NYU Grossman School of Medicine, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Albert Einstein College of Medicine, Bronx, NY, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Northwell Health, Manhasset, NY, ⁹Johns Hopkins School of Medicine, Baltimore, MD, ¹⁰Brigham and Women's Hospital, Everett, MA, ¹¹Texas Tech University Health Sciences Center, Texas, TX, ¹²Texas Tech University Health Sciences Center, El Paso, TX, ¹³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ¹⁴University of Michigan, Ann Arbor, MI, ¹⁵University of California San Francisco, Corte Madera, CA, ¹⁶University of California San Francisco, San Francisco, CA, ¹⁷Medical University of South Carolina, Charleston, SC, ¹⁸UC San Diego, La Jolla, CA, ¹⁹Multiple Institutions, Multiple Cities, ²⁰Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Lupus nephritis can occur as an isolated component of disease activity or be accompanied by diverse extrarenal symptoms that can adversely affect a patient’s…
Abstract Number: 1421 • ACR Convergence 2021
Efficacy and Tolerance of Vaccination Against COVID-19 in Patients with Systemic Lupus Erythematosus: The International VACOLUP Study
Renaud Felten¹, Lou KAWKA², Maxime DUBOIS², Manuel Ugarte-Gil³, Yurilis Fuentes-Silva⁴, Matteo PIGA⁵ and Laurent Arnaud¹, ¹Department of Rheumatology, French National Reference Center for Autoimmune Diseases (CRMR RESO), Strasbourg, France, ²National Reference Center for Rare East South-West Autoimmune Systemic Diseases RESO, Strasbourg University Hospitals, Strasbourg, France, ³Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ⁴Division of Rheumatology, Complejo Hospitalario Universitario Ruiz y Páez, Universidad de Oriente, Ciudad Bolívar, Centro Nacional de Enfermedades Reumáticas, Ciudad Bolívar, Venezuela, ⁵Department of Medical Science and Public Health, University of Cagliari, Cagliary, Italy
Background/Purpose: Both efficacy and safety data regarding COVID vaccines in systemic lupus erythematosus (SLE) are lacking. We conducted the international Vaccination Against COvid in systemic…
Abstract Number: 1480 • ACR Convergence 2021
LncRNA XIST Alters the Balance of Peripheral Blood Immune Cells in Systemic Lupus Erythematosus by Regulating the miR-17-92/OFLM4 and CEACAM8 Axis
Qi Cheng, Mo Chen, xin Chen, peiyu zhang, huaxiang wu and yan du, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China (People's Republic)
Background/Purpose: X-inactive-specific transcript (XIST) has been shown to silence linked genes on the X chromosome that may be related to the pathogenesis of systemic lupus…
Abstract Number: 1500 • ACR Convergence 2021
Expression of Neuropilin-1 Is Significantly Increased in Dendritic Cells and CD4 + T Cells and It Correlates Disease Activity in the Patients with Systemic Lupus Erythematosus
Yunjung Choi¹, Eun-gyeong Lee¹, Yu-Mi Lee², Myeung-Su Lee³, Chang-Hoon Lee³, Chong Hyuk Chung³ and Wan-Hee yoo¹, ¹Research Institute of Clinical Medicine of Jeonbuk national university-Biomedical Research Institute of Jeonbuk national university hospital, Jeonju, Republic of Korea, ²Jeonbuk National University Hospital, Jeonju, Republic of Korea, ³Wonkwang University Hospital, Iksan, Republic of Korea
Background/Purpose: Neuropilin-1 (NRP-1) is a transmembrane glycoprotein that acts as a receptor of class III/IV semaphorins which role in the pathogenesis of autoimmune diseases. The…
Abstract Number: 1643 • ACR Convergence 2021
Increased Incidence of Pediatric SLE and Other Interferon Activated Diseases During COVID-19 Pandemic
Xinyu Dou¹, David Kaelber² and Hulya Bukulmez¹, ¹MetroHealth Medical Center, Case Western Reserve, Cleveland, OH, ²The MetroHealth System Campus of Case Western Reserve University, Cleveland, OH
Background/Purpose: COVID-19, as a member of the Coronavirus family, has been described to trigger host immune response via type I interferon (IFN) signaling pathways with…
Abstract Number: 1741 • ACR Convergence 2021
Anifrolumab Results in Favorable Responses Regardless of SLE Disease Duration: Post Hoc Analysis of Data from 2 Phase 3 Trials
Kenneth Kalunian¹, Maria Dall'Era², Richard Furie³, Eric Morand⁴, Konstantina Psachoulia⁵, Emmanuelle Maho⁶, Catharina Lindholm⁷ and Raj Tummala⁵, ¹University of California, La Jolla, CA, ²University of California San Francisco, San Francisco, CA, ³Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ⁴Monash University, Melbourne, Australia, ⁵BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁶BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁷BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: In 2 phase 3 trials, TULIP-1 and TULIP-2, anifrolumab, a type I IFN receptor mAb, improved disease activity in patients with SLE.1,2 Here, we…
Abstract Number: 1759 • ACR Convergence 2021
An Analysis of Medication Responsiveness Based on Subtype and Race Within a Cohort of Cutaneous Lupus Erythematosus Patients
Emily Keyes¹, Anisha Jobanputra², Madison Grinnell³, Rui Feng⁴, Thomas Vazquez⁵, DeAnna Diaz⁶ and Victoria Werth⁷, ¹Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ²Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, OMAHA, NE, ⁴University of Pennsylvania Department of Biostatistics, Philadelphia, PA, ⁵FIU Wertheim College of Medicine, Virginia Beach, VA, ⁶Philadelphia College of Medicine, Philadelphia, PA, ⁷Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cutaneous lupus erythematosus (CLE) can present in association with or without concomitant SLE, and with skin manifestations varying by subtype – acute CLE, subacute…
Abstract Number: 1929 • ACR Convergence 2021
Metabolomics Identifies Early Mechanisms of Atherogenic Dyslipidaemia in Juvenile-SLE Patients Associated with Inflammation
George Robinson¹, Kirsty Waddington¹, Junjie Peng¹, Anna Radziszewska¹, David Isenberg², Yiannis Ioannou¹, Ines Pineda-Torra¹, Coziana Ciurtin¹ and Elizabeth Jury¹, ¹University College London, London, United Kingdom, ²Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Cardiovascular disease (CVD) is a leading cause of mortality in patients with juvenile-onset systemic lupus erythematosus (JSLE) through atherosclerosis, the build-up of lipids and…
Abstract Number: 0229 • ACR Convergence 2021
The Effects of Self-efficacy on Fatigue and Pain Interference in Black Women with Systemic Lupus Erythematosus: The Role of Depression, Age, and Education
Cristina Drenkard¹, Kirk Easley¹, Gaobin Bao¹, Charmayne Dunlop-Thomas¹, Teresa Brady² and S Sam Lim³, ¹Emory University, Atlanta, GA, ²Clarity Consulting and Communications, Atlanta, GA, ³Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Fatigue and pain are pervasive symptoms that cause escalating distress in patients with SLE, particularly among Black women and other high-risk groups. While these…
Abstract Number: 0336 • ACR Convergence 2021
The Incremental Clinical Utility of a Multianalyte Assay Panel with Cell-Bound Complement Activation Products versus a Traditional ANA Testing Strategy for the Diagnosis and Treatment of SLE
Tyler O'Malley¹, Fenglong Xie², yujie Su², cassie Clinton², Debra J. Zack¹, Jeffrey Curtis³ and John Wegener¹, ¹Exagen Inc., Vista, CA, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The comparative clinical utility of various diagnostic tests to aid the differential diagnosis of SLE is unclear. We compare the outcomes of testing with…
Abstract Number: 0355 • ACR Convergence 2021
Utilization of a Clinical Data Research Network to Assess Systemic Lupus International Collaborating Clinics Classification Criteria Attributes in Patients with Systemic Lupus Erythematosus
Noah Forrest¹, Kathryn Jackson², Al'ona Furmanchuk², Anika Ghosh², Jennifer Pacheco², Vesna Mitrovic², Abel Kho², Rosalind Ramsey-Goldman² and Theresa Walunas², ¹Feinberg School of Medicine, Chicago, ²Northwestern University, Chicago, IL
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by a heterogenous clinical phenotype that may present differently over time and between patients, which…
Abstract Number: 0540 • ACR Convergence 2021
Behavioral Deficits May Precede Influx of Brain-Infiltrating Macrophages in Neuropsychiatric Symptoms of Systemic Lupus Erythematosus
Hadijat Makinde, Miranda Gurra, Yidan Wang, Sara Radecki and Carla Cuda, Northwestern University, Chicago, IL
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that affects many end organs including the brain. Despite a prevalence of over 50% in…
Abstract Number: 0629 • ACR Convergence 2021
Patient and Physician Satisfaction with Telemedicine Utilization for Delivery of Care in Patients with SLE – A Single Centre Experience
Tanmayee Bichile¹, Amanda Bembic², Susan Manzi¹ and Sonia Manocha¹, ¹Allegheny Health Network, Pittsburgh, PA, ²Allgheny Health Network, Pittsburgh, PA
Background/Purpose: COVID 19 has forced the healthcare system to utilize telemedicine to provide dependable and timely care for patients with SLE. Telemedicine has been used…
Abstract Number: 0860 • ACR Convergence 2021
Associations Between Tricarboxylic Acid Cycle Plasma Metabolites and Fatigue Phenotypes in Black Females with Systemic Lupus Erythematosus: An Untargeted Metabolomics Analysis
Laura Kimble¹, Arezou Khosroshahi¹, Glenna Brewster¹, Nicole Carlson¹, Ronald Eldridge¹ and Elizabeth Corwin², ¹Emory University, Atlanta, GA, ²Columbia University, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) occurs predominantly in women and Black women have disproportionately poorer health outcomes across the trajectory of their disease compared to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].